nitroflurbiprofen has been researched along with Kidney Diseases in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
de Nucci, G; Fujihara, CK; Gonçalves, AR; Malheiros, DM; Mattar, AL; Noronha, Ide L; Zatz, R | 1 |
Fevery, J; Laleman, W; Nevens, F; Van der Elst, I; Van Landeghem, L; Zeegers, M | 1 |
2 other study(ies) available for nitroflurbiprofen and Kidney Diseases
Article | Year |
---|---|
Renal expression of COX-2, ANG II, and AT1 receptor in remnant kidney: strong renoprotection by therapy with losartan and a nonsteroidal anti-inflammatory.
Topics: Angiotensin II; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Cyclooxygenase 2; Drug Therapy, Combination; Flurbiprofen; Hypertension, Renal; Immunohistochemistry; Isoenzymes; Kidney; Kidney Diseases; Losartan; Male; Nephrectomy; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1 | 2004 |
Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
Topics: Animals; Cyclooxygenase Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelium, Vascular; Flurbiprofen; Hypertension, Portal; Kidney Diseases; Liver; Liver Circulation; Liver Cirrhosis, Experimental; Male; Nitric Oxide; Nitric Oxide Donors; Peptic Ulcer; Perfusion; Portal Pressure; Rats; Rats, Wistar; Thioacetamide; Thromboxane A2; Vascular Resistance; Vasoconstriction; Vasodilation | 2007 |